Two Sigma Advisers LP purchased a new stake in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 68,100 shares of the company's stock, valued at approximately $842,000.
A number of other hedge funds have also modified their holdings of WVE. Price T Rowe Associates Inc. MD grew its position in shares of Wave Life Sciences by 63.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company's stock valued at $63,074,000 after purchasing an additional 1,972,262 shares during the period. Loomis Sayles & Co. L P acquired a new stake in Wave Life Sciences during the 4th quarter worth approximately $20,545,000. Polar Capital Holdings Plc bought a new position in Wave Life Sciences in the fourth quarter valued at approximately $12,370,000. MPM Bioimpact LLC boosted its holdings in shares of Wave Life Sciences by 138.5% in the fourth quarter. MPM Bioimpact LLC now owns 1,489,237 shares of the company's stock valued at $18,422,000 after buying an additional 864,766 shares during the period. Finally, Driehaus Capital Management LLC boosted its holdings in shares of Wave Life Sciences by 14.6% in the fourth quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company's stock valued at $83,033,000 after buying an additional 853,589 shares during the period. 89.73% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, Director Christian O. Henry sold 10,500 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $9.77, for a total value of $102,585.00. Following the completion of the sale, the director now directly owns 16,115 shares in the company, valued at approximately $157,443.55. This trade represents a 39.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 29.10% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of brokerages recently commented on WVE. Jefferies Financial Group initiated coverage on shares of Wave Life Sciences in a report on Tuesday, February 25th. They set a "buy" rating and a $26.00 price objective on the stock. Wedbush assumed coverage on Wave Life Sciences in a research note on Tuesday, April 8th. They issued an "outperform" rating and a $18.00 price target on the stock. Wall Street Zen lowered Wave Life Sciences from a "hold" rating to a "sell" rating in a report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Finally, Cantor Fitzgerald initiated coverage on Wave Life Sciences in a report on Tuesday, April 29th. They set an "overweight" rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $21.17.
Read Our Latest Report on Wave Life Sciences
Wave Life Sciences Stock Performance
WVE traded up $0.47 on Friday, hitting $7.22. 1,345,377 shares of the company were exchanged, compared to its average volume of 1,311,291. The stock's fifty day moving average is $6.44 and its 200-day moving average is $10.04. Wave Life Sciences Ltd. has a 12 month low of $4.25 and a 12 month high of $16.74. The company has a market cap of $1.11 billion, a PE ratio of -6.50 and a beta of -0.92.
Wave Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The company had revenue of $9.18 million for the quarter, compared to analyst estimates of $11.65 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. During the same period last year, the firm earned ($0.24) EPS. As a group, equities research analysts expect that Wave Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.
Wave Life Sciences Profile
(
Free Report)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Featured Stories
Before you consider WAVE Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.
While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
